Poster presented by C. Pensec (Biofortis) at “PROBIOTA Congress” Amsterdam, “Onco Week” Toulouse and “4th R&D Business collaboration forum Europe” London02/02/2016
Poster présenté par JF Mirjolet (Oncodesign) au congrès annuel de l’AACR (USA, New Orleans, 16-20 avril 2016)16/04/2016
Studying cytarabine resistance through PDX models
in acute myeloid leukemia
Introduction The major therapeutic barrier in acute myeloid leukemia (AML) is chemotherapy resistance.
AML cells resistant to conventional chemotherapy targeting DNA synthesis are thought to be enriched in quiescent leukemic stem cells (LSCs). In order to better understand chemotherapy resistance in AML, we analyzed the response to cytarabine (AraC) through patient-derived xenograft (PDX) models with 20 primary AML patient specimens from two clinical sites and in the context of a French “Innovative models initiative” (IMODI) program.